You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昭衍新藥(06127.HK)業績快報:2021年度淨利同比增長76.83% 全年新簽訂單超28億元

格隆匯2月24日丨昭衍新藥(06127.HK)披露2021年度業績快報,2021年度,公司營業總收入為人民幣15.17億元,同比增長40.99%;歸屬於上市公司股東的淨利潤為人民幣5.57億元,同比增長76.83%;歸屬於上市公司股東的扣除非經常性損益的淨利潤為人民幣5.30億元,同比增長81.51%;基本每股盈利為人民幣1.51元。

公司業績保持較好增長,資產及權益大幅上漲,主要源於以下幾個方面:

1.主營業務影響

(1)公司始終強化技術創新,率先建立了行業創新型藥物評價技術平台並規範化。持續加強對創新型藥物、新技術平台原始創新的研發支持,深得創新型研發企業信賴,全年新簽訂單超28億元,截止報吿期末,在手訂單超29億元。

(2)公司科研技術團隊規模擴大,擁有越來越多成熟的技術人員;進一步優化和完善實驗設施及項目管理流程,實驗室產能利用率持續提升,保證在手訂單得到高效執行;供應端也為業績增長提供了有力支撐。

(3)公司持續提升資金管理能力,為公司業績帶來積極影響。

2.非經營性損益的影響

主要受政府補助、交易性金融資產收益、港股募集資金結匯損失等多因素影響,扣除所得税後非經常性損益對淨利潤的影響金額約人民幣2,700萬元,比去年同期增加約人民幣400萬元。

3.H股上市的影響

公司於2021年2月在香港順利IPO,融資後導致股本及淨資產等指標大幅增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account